

**AMENDMENTS TO THE CLAIMS:**

The listing of claims will replace all prior versions, and listings of claims in the application:

**LISTING OF THE CLAIMS**

1. (Previously Presented) A method of treating diseases of the skin and mucous membrane caused by herpes simplex virae, said method comprising the administration to the area to be treated of the alkali and/or alkaline earth salts of tosylchloramide.

Claim 2 (Cancelled)

3. (Previously Presented) The method of Claim 1, characterized in that the diseases result in efflorescenses.

Claim 4 (Cancelled)

Claim 5 (Cancelled)

6. (Previously Presented) The method of Claim 1, characterized in that the diseases affect:

- a) the lid, conjunctiva or cornea of the eye;
- b) the exterior of the ear;
- c) the nasal cavity;
- d) the lips and mucous membranes of the mouth and/or the tongue;
- e) the vulva and/or vagina;
- f) the penis;
- g) the anus;
- h) the nail;
- i) the hair follicles and/or the sebaceous glands; and/or
- j) the hands and feet.

7. (Previously Presented) The method of Claim 1, wherein said tosylchloramide salt(s), are present in an employed base in an amount of approximately 0.1 to 20% by weight.
8. (Previously Presented) The method of Claim 1, wherein sodium tosylchloramide salt is employed.
9. (Previously Presented) The method of Claim 7, wherein said base constitutes a liquid, semi-solid or solid, water-containing or water-free galenic preparation.
10. (Previously Presented) The method of Claim 9, wherein said base constitutes an ointment, a gel, a cream, a paste, a suppository, such as a vaginal suppository, an adhesive bandage, a tablet, such an effervescent or vaginal tablet, or a capsule, a stick, a pulverized substance, a powder, a solution, an aerosol, a two-compartment system or a suspension, such as a shake mixture/dry suspension.
11. (Previously Presented) The method of Claim 9, wherein said base constitutes a dosed aerosol or a dosed solution.
12. (Previously Presented) The method of Claim 9, wherein said base constitutes a bath water additive.
13. (Previously Presented) The method of Claim 9, wherein said base is an O/W- or a W/O-emulsion ointment.
14. (Previously Presented) The method of Claim 7, wherein said base is a cortisone-containing preparation, containing said tosylchloramide salt(s), in an amount of approximately 0.1 to 20% by weight.
15. (Previously Presented) The method of Claim 9, wherein said base is a gel comprising said tosylchloramide salt(s), in an amount of approximately 0.1 to 5% by

weight.

16. (Previously Presented) The method of Claim 9, wherein a bath water additive is employed in form of pulverized substance or bath salt tablet or effervescent tablet, which is applied in water in a concentration of approximately 0.1 to 1% by weight.

17. (Previously Presented) The method of Claim 1, wherein said tosylchloramide salt(s), are present in an employed base in an amount of approximately 5 to 15% by weight.

18. (Previously Presented) The method of Claim 1, wherein said tosylchloramide salt(s), are present in an employed base in an amount of approximately 8 to 12% by weight.

19. (Previously Presented) The method of Claim 9, wherein the base is a gel, in which are present said tosylchloramide salt(s), in an amount of approximately 0.1 to 2% by weight.

20. (Previously Presented) The method of claim 1, further comprising a treatment schedule including an application duration from about 2 to about 20 days and an application frequency from about 1 to about 4 times per day.

21. (Previously Presented) The method of claim 1, further comprising a treatment schedule including an application duration from about 2 to about 6 days and an application frequency from about 1 to about 3 times per day.

22. – 33 Cancel

34. (New) A method of treating diseases of the skin and mucous membranes caused by the herpes simplex virae comprising:

application of a medicament, to the area to be treated, having a salt of tosylchloramide selected from the group consisting of alkali salts, alkaline earth salts and mixtures thereof in an employed base in an amount of approximately 0.1 to 20% by weight.

35. (New) The method of claim 34, wherein said base constitutes a liquid, semi-solid or solid, water-containing or water-free galenic preparation.

36. (New) The method of claim 35, wherein said base constitutes an ointment, a gel, a cream, a paste, a suppository, such as a vaginal suppository, an adhesive bandage, a tablet, such an effervescent or vaginal tablet, or a capsule, a stick, a pulverized substance, a powder, a solution, an aerosol, a two-compartment system or a suspension, such as a shake mixture/dry suspension.

37. (New) The method of claim 35, wherein said base constitutes a dosed aerosol or a dosed solution.

38. (New) The method of claim 35, wherein said base constitutes a bath water additive.

39. (New) The method of claim 35, wherein said base is an O/W- or a W/O-emulsion ointment.

40. (New) The method of claim 34, wherein said base is a cortisone-containing preparation, containing said tosylchloramide salt(s), in an amount of approximately 0.1 to 20% by weight.

41. (New) The method of claim 35, wherein said base is a gel comprising said tosylchloramide salt(s), in an amount of approximately 0.1 to 5% by weight.

42. (New) The method of claim 35, wherein the bath water additive is employed in form of pulverized substance or bath salt tablet or effervescent tablet, which is applied

in water in a concentration of approximately 0.1 to 1% by weight.

43. (New) The method of claim 34, wherein said tosylchloramide salt(s), are present in an employed base in an amount of approximately 5 to 15% by weight.

44. (New) The method of claim 34, wherein said tosylchloramide salt(s), are present in an employed base in an amount of approximately 8 to 12% by weight.

45. (New) The method of claim 35, wherein the base is a gel, in which are present said tosylchloramide salt(s), in an amount of approximately 0.1 to 2% by weight.